Spruce Biosciences Reports Full-Year 2025 Financial Results and Provides Key Corporate Updates

Executive Summary

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company specializing in therapies for neurological disorders with significant unmet medical need, has reported its financial results for the year ended December 31, 2025, alongside major corporate developments. The company delivered a highly productive year, focusing chiefly on the advancement of its tralesinidase alfa enzyme replacement therapy (TA-ERT) program for Sanfilippo Syndrome Type B (MPS IIIB).

Key Highlights

• TA-ERT BLA Submission on Track: Following positive FDA Type B meetings, the Biologics License Application (BLA) for TA-ERT is scheduled for Q4 2026, positioning TA-ERT as a potential first-in-class, disease-modifying therapy for MPS IIIB, a condition with currently no approved treatments.
• Regulatory Milestone: The FDA confirmed that Spruce’s integrated clinical and natural history data could be sufficient for accelerated approval, using cerebral spinal fluid heparan sulfate as a surrogate endpoint. This presents a clear regulatory pathway and significantly de-risks the program.
• Commercial Leadership Strengthened: Dale Hooks, a veteran with over 30 years of rare disease commercialization experience, has been appointed as Chief Commercial Officer to prepare for potential launch.
• Strengthened Financial Position: Secured up to \$50 million in growth capital from Avenue Capital Group via a loan facility, including an initial \$15 million tranche fully funded in January 2026.
• Positive Long-term Data: Presented at WORLDSymposium, data showed rapid and durable reductions in heparan sulfate and preservation of cognitive and non-cognitive outcomes with TA-ERT, including compelling sibling case studies.
• Rare Pediatric Disease PRV Program Reauthorized: PRV program extended through 2029, restoring a valuable incentive for rare pediatric therapies. TA-ERT, if approved, will be eligible for a transferable Priority Review Voucher (PRV).
• Board and Leadership Additions: Regulatory and clinical development expertise deepened with the appointments of Daven Mody, Pharm.D. (SVP, Regulatory & Quality) and Bruno Gagnon, B.Pharm., M.Sc. (SVP, Clinical Development Ops). Keli Walbert, an experienced commercial leader, also joined the Board of Directors.

2025 Financial Results

• Cash and Cash Equivalents: \$48.9 million as of December 31, 2025 (excluding the \$15 million Avenue Capital loan funded in January 2026). The company expects this to fund operations into early 2027, past the anticipated TA-ERT BLA submission.
• R&D Expenses: \$19.5 million (down from \$46.4 million in 2024), reflecting the cessation of tildacerfont development for CAH and focus on TA-ERT and the acquisition of SPR202 for CAH.
• G&A Expenses: \$17.0 million (up from \$14.6 million in 2024), mainly due to increased professional service fees.
• Total Operating Expenses: \$36.5 million (down from \$61.1 million in 2024). Includes \$2.6 million in non-cash stock-based compensation (down from \$5.3 million in 2024).
• Net Loss: \$39.0 million (improved from \$53.0 million in 2024).

Other Noteworthy Developments

• TA-ERT Clinical Data: Long-term data, including case studies of siblings with MPS IIIB, suggest that TA-ERT provides tangible cognitive, language, and motor function benefits compared to untreated patients.
• Access to Additional Capital: The Avenue Capital loan facility provides flexibility, supporting TA-ERT’s late-stage development and potential commercial launch. Three further tranches of up to \$35 million remain, contingent on the achievement of milestones.

Potential Shareholder Impact

• Regulatory Clarity and Acceleration: The FDA’s positive feedback and willingness to consider accelerated approval based on surrogate endpoints is a highly price-sensitive development, reducing regulatory risk and opening the path to earlier market access for TA-ERT.
• Commercial Readiness: The appointment of a highly experienced Chief Commercial Officer and Board member signals Spruce’s readiness for commercialization, which is critical for unlocking shareholder value if TA-ERT is approved.
• Financial Flexibility: The growth capital secured ensures sufficient runway to reach and potentially surpass the TA-ERT approval milestone, addressing a key investor concern in biotech development cycles.
• Rare Pediatric Disease PRV: If TA-ERT is approved, the PRV could be a valuable, monetizable asset, sometimes trading for over \$100 million, further enhancing shareholder value.
• Improvement in Financial Results: Lower net loss and operating expenses, prudent capital management, and a strategic shift to higher-value programs are all positive signals for investors.

Conclusion

Spruce Biosciences’ 2025 results and corporate actions position the company for a transformational 2026, with clear regulatory guidance, strong financial backing, and a commercial team in place for a potential first-in-class launch in MPS IIIB. The next 12–24 months are critical, with the anticipated BLA submission for TA-ERT and further clinical readouts potentially serving as major share price catalysts. Investors should closely monitor regulatory milestones, further clinical updates, and any partnership or monetization developments related to the PRV.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consider their individual investment objectives and risk tolerance before making investment decisions. Forward-looking statements are subject to risks and uncertainties as outlined in Spruce Biosciences’ SEC filings.

View SPRUCE BIOSCIENCES, INC. Historical chart here